Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome
- 1 November 2017
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 29 (11) , 1247-1250
Abstract
Background: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis, with poor survival. Rifaximin is a gut-selective broad-spectrum antibiotic. Aim: The aim of this study was to evaluate the role of rifaximin as a primary prevention of HRS. Patients and methods: Eighty patients with liver cirrhosis and ascites were enrolled. They were randomized into two groups: control (n=40) and rifaximin group (n=40). Baseline liver function tests, renal function tests, complete blood count, international normalized ratio, urine analysis, and abdominal ultrasonography were carried out. Rifaximin 550 mg was administered twice daily for 12 weeks. Renal functions were measured every 4 weeks with monitoring of HRS occurrence and possible precipitating factor. Results: Both groups were matched for age, sex, virology, serum bilirubin, serum albumin, aspartate aminotransferase, alanine aminotransferase, hemoglobin, white blood cells, platelets, international normalized ratio, potassium, and Child–Pugh score. In contrast to the rifaximin group, the control group showed statistically significant serial blood urea nitrogen (18.84±7.17, 19.85±6.10, 21.54±4.79, and 22.96±5.82 mg/dl; P=0.001) and serum creatinine (0.94±0.25, 1.02±0.24, 1.12±0.16, and 1.21±0.17 mg/dl; P=0.001) levels. The overall blood urea nitrogen and serum creatinine change was statistically higher in the control group than the rifaximin group (20.8 vs. 18.24 mg/dl and 1.07 vs. 0.99 mg/dl, respectively). HRS developed more in the control group than the rifaximin group [9 (22.5%) vs. 2 (5%); P=0.048]. In both groups, HRS was precipitated by spontaneous bacterial peritonitis mainly and large volume paracentesis. The Child–Pugh score, control group, baseline serum sodium, and creatinine were predictors of HRS. Conclusion: Rifaximin may be useful as a primary prevention of HRS.Keywords
This publication has 22 references indexed in Scilit:
- Hepatorenal Syndrome: Aetiology, Diagnosis, and TreatmentGastroenterology Research and Practice, 2015
- Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic EncephalopathyClinical Gastroenterology and Hepatology, 2014
- Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromesLiver International, 2014
- Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and AscitesPLOS ONE, 2014
- Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosisJournal of Gastroenterology and Hepatology, 2013
- The Role of Rifaximin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Patients With Liver CirrhosisJournal of Clinical Gastroenterology, 2012
- Rifaximin Improves Systemic Hemodynamics and Renal Function in Patients With Alcohol-Related Cirrhosis and AscitesClinical Gastroenterology and Hepatology, 2012
- Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled studyAlimentary Pharmacology & Therapeutics, 2011
- Liver cirrhosisBest Practice & Research Clinical Gastroenterology, 2011
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006